Compare SLNG & FBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLNG | FBIO |
|---|---|---|
| Founded | 2013 | 2006 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.2M | 113.9M |
| IPO Year | N/A | N/A |
| Metric | SLNG | FBIO |
|---|---|---|
| Price | $5.25 | $3.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $10.00 | ★ $16.50 |
| AVG Volume (30 Days) | 17.3K | ★ 540.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.02 | $29.71 |
| Revenue Next Year | $7.68 | $49.34 |
| P/E Ratio | $91.68 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.29 | $1.33 |
| 52 Week High | $8.08 | $4.53 |
| Indicator | SLNG | FBIO |
|---|---|---|
| Relative Strength Index (RSI) | 44.48 | 51.47 |
| Support Level | $5.41 | $3.45 |
| Resistance Level | $5.66 | $3.70 |
| Average True Range (ATR) | 0.24 | 0.24 |
| MACD | -0.06 | 0.03 |
| Stochastic Oscillator | 8.65 | 67.98 |
Stabilis Solutions Inc is an energy transition company that provides turnkey clean energy production, storage, transportation, and fueling solutions using liquefied natural gas (LNG) to multiple end markets. The company provides LNG solutions to customers in diverse end markets, including aerospace, agriculture, energy, industrials, marine bunkering, mining, pipeline, remote power, and utility markets. It generates revenue by selling and delivering LNG to its customers, renting cryogenic equipment, and providing engineering and field support services. It has a geographical presence in the United States and Mexico.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.